Search Results 1611-1620 of 18740 for Activation

  1. Tafasitamab, Lenalidomide and Venetoclax for the Treatment of Relapsed or Refractory Mantle Cell Lymphoma - Mayo Clinic

    * Activated partial thromboplastin time (aPTT) or partial thromboplastin time (PTT) =\< 1.5 × upper normal limit (ULN) (obtained =\< 14 days prior to ...

  2. Clinical trials - Oncology (Medical)

    We present here a CAR design that allows PD-1 to recognize PD-L1 on the tumor; however, the intracellular CAR design is one that results in T cell activation as ...

  3. Clinical trials - Oncology (Medical)

    We present here a CAR design that allows PD-1 to recognize PD-L1 on the tumor; however, the intracellular CAR design is one that results in T cell activation as ...

  4. A Study Comparing Ibrutinib and Obinutuzumab With or Without Venetoclax in Treating Patients with Chronic Lymphocytic Leukemia - Mayo Clinic

    Prothrombin time (PT)/international normalized ratio (INR) < 1.5 ULN and partial thromboplastin time (PTT) (activated partial thromboplastin time [aPTT]) ...

  5. Tucatinib, Trastuzumab, Ramucirumab, and Paclitaxel Versus Paclitaxel and Ramucirumab in Previously Treated HER2+ Gastroesophageal Cancer - Mayo Clinic

    International normalized ratio (INR) ≤ 1.5, and prothrombin time (PT) and partial thromboplastin time (PTT)/activated partial thromboplastin time (aPTT) ...

  6. A Study to Evaluate ASP0367 in Participants With Primary Mitochondrial Myopathy (MOUNTAINSIDE) - Mayo Clinic

    randomization. - Participant has used any peroxisome proliferator-activated receptor (PPAR) ligands such as fibrates and thiazolidinediones within 4 weeks ...

  7. Zebrafish PKD-Targeted Services - Model Systems Core - Mayo Clinic Research

    Robust activation of microhomology-mediated end joining for precision gene editing applications. PLOS Genetics. 2018; doi:10.1371/journal.pgen.1007652 ...

  8. pain medication Archives - Mayo Clinic News Network

    ... activates those opioid receptors, the receptors say, 'OK, we've got our opioid again.' It becomes something else you have to withdraw from again." Natural ...

  9. Publications - Michael W. Ruff, M.D. - Mayo Clinic

    GM-CSF disruption in CART cells modulates T cell activation and enhances CART cell anti-tumor activity. Leukemia. 2022 Jun; 36(6):1635-1645. Epub 2022 Apr ...

  10. Dabrafenib Combined With Trametinib After Radiation Therapy in Treating Patients With Newly-Diagnosed High-Grade Glioma - Mayo Clinic

    Patients with a history of a malignancy with confirmed activating RAS mutation. History of allergic reactions attributed to compounds of similar chemical or ...